# OnCo record pnt2003 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pnt2003/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pnt2003" ;
  schema:name "Lutetium Lu 177 dotatate (PNT2003)"@en ;
  schema:alternateName "PNT2003"@en, "177Lu-PNT2003"@en ;
  schema:description "PNT2003 is a generic version of Lutathera, the radioactive treatment for neuroendocrine tumours of the gut and pancreas. Lantheus licensed it from POINT Biopharma and received tentative FDA approval in March 2026; full approval was waiting on a patent dispute."@en ;
  schema:url <https://onco.cc/drugs/pnt2003/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.biospace.com/press-releases/lantheus-receives-fda-tentative-approval-for-lutetium-lu-177-dotatate-pnt2003-radioequivalent-to-lutathera>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55> ;
  onco:status "emerging" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Radioligand therapy (beta), generic radioequivalent of Lutathera" ;
  onco:related <https://onco.cc/drugs/lutathera/> ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:companies <https://onco.cc/companies/lantheus/>, <https://onco.cc/companies/point-biopharma/> .